documents: FDA-2020-N-2252-0001
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | agency_id | docket_id | title | document_type | subtype | posted_date | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2020-N-2252-0001 | FDA | FDA-2020-N-2252 | Interim Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act; Public Meeting; Request for Comments | Notice | Request for Comments | 2020-12-28T05:00:00Z | 2020 | 12 | 2020-12-28T05:00:00Z | 2021-03-30T03:59:59Z | 2021-03-30T01:00:27Z | 2020-28602 | 0 | 0 | 09000064849cc7ab |
Links from other tables
- 1 row from regs_document_id in fr_regs_crossref